U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886074) titled 'Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL' on March 03.
Brief Summary: Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS). Patients who are MRD positive and have no access to novel immunotherapies should receive an allogeneic hematopoietic stem cell transplantation (HSCT). Blinatumomab is considered a standard of care (SOC) for this group of patients, however, the ideal treatment dose for MRD is unknown as doses were adjusted from the relapsed/refractory setting. Preli...